High-risk medulloblastoma: A pediatric oncology group randomized trial of chemotherapy before or after radiation therapy (POG 9031)

Journal of Clinical Oncology

Volumn 31, Issue 23, 2013, Pages 2936-2941

  Tarbell, Nancy J ^a   Friedman, Henry ^b   Polkinghorn, William R ^c   Yock, Torunn ^a   Zhou, Tianni ^d   Chen, Zhengjia ^f   Burger, Peter ^g   Barnes, Patrick ^e   Kun, Larry ^h  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b DUKE UNIVERSITY   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d CALIFORNIA STATE UNIVERSITY   (United States)

^e STANFORD UNIVERSITY   (United States)

^f EMORY UNIVERSITY   (United States)

^g JOHNS HOPKINS HOSPITAL   (United States)

^h ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; ETOPOSIDE; MESNA; VINCRISTINE; ANTINEOPLASTIC AGENT;

ADOLESCENT; ADULT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER SURGERY; CANCER SURVIVAL; CHILD; CHILDHOOD CANCER; CLINICAL OUTCOME; COMPARATIVE STUDY; CONFERENCE PAPER; CONSOLIDATION CHEMOTHERAPY; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDULLOBLASTOMA; MINIMAL RESIDUAL DISEASE; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; OSSIFYING FIBROMA; OVERALL SURVIVAL; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT RESPONSE; TUMOR VOLUME; CANCER STAGING; CEREBELLAR NEOPLASMS; CHEMORADIOTHERAPY; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; MULTICENTER STUDY; PATHOLOGY; PRESCHOOL CHILD; PROCEDURES; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; YOUNG ADULT;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CEREBELLAR NEOPLASMS; CHEMORADIOTHERAPY; CHILD; CHILD, PRESCHOOL; CISPLATIN; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; ETOPOSIDE; FEMALE; HUMANS; MALE; MEDULLOBLASTOMA; NEOPLASM STAGING; PROGNOSIS; RISK FACTORS; VINCRISTINE; YOUNG ADULT;

EID: 84886726351     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.43.9984     Document Type: Conference Paper

References (21)

1. Gurney JG, Davis S, Severson RK, et al: Trends in cancer incidence among children in the U.S. Cancer 78:532-541, 1996
2. McNeil DE, Coté TR, Clegg L, et al: Incidence and trends in pediatric malignancies medulloblastoma/primitive neuroectodermal tumor: A SEER update-Surveillance Epidemiology and End Results. Med Pediatr Oncol 39:190-194, 2002
3. Polkinghorn WR, Tarbell NJ: Medulloblastoma: Tumorigenesis, current clinical paradigm, and efforts to improve risk stratification. Nat Clin Pract Oncol 4:295-304, 2007
4. Evans AE, Jenkin RD, Sposto R, et al: The treatment of medulloblastoma: Results of a prospective randomized trial of radiation therapy with and without CCNU, vincristine, and prednisone. J Neurosurg 72:572-582, 1990
5. Tait DM, Thornton-Jones H, Bloom HJ, et al: Adjuvant chemotherapy for medulloblastoma: The first multi-centre control trial of the International Society of Paediatric Oncology (SIOP I). Eur J Cancer 26:464-469, 1990
6. Packer RJ, Sutton LN, Elterman R, et al: Outcome for children with medulloblastoma treated with radiation and cisplatin, CCNU, and vincristine chemotherapy. J Neurosurg 81:690-698, 1994
7. Bailey CC, Gnekow A, Wellek S, et al: Prospective randomised trial of chemotherapy given before radiotherapy in childhood medulloblastoma: International Society of Paediatric Oncology (SIOP) and the (German) Society of Paediatric Oncology (GPO)-SIOP II. Med Pediatr Oncol 25:166-178, 1995
8. Zeltzer PM, Boyett JM, Finlay JL, et al: Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: Conclusions from the Children's Cancer Group 921 randomized phase III study. J Clin Oncol 17:832-845, 1999
9. Kortmann RD, Kühl J, Timmermann B, et al: Postoperative neoadjuvant chemotherapy before radiotherapy as compared to immediate radiotherapy followed by maintenance chemotherapy in the treatment of medulloblastoma in childhood: Results of the German prospective randomized trial HIT '91. Int J Radiat Oncol Biol Phys 46:269-279, 2000
10. Taylor RE, Bailey CC, Robinson KJ, et al: Outcome for patients with metastatic (M2-3) medulloblastoma treated with SIOP/UKCCSG PNET-3 chemotherapy. Eur J Cancer 41:727-734, 2005
11. Gajjar A, Chintagumpala M, Ashley D, et al: Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): Long-term results from a prospective, multicentre trial. Lancet Oncol 7:813-820, 2006
12. Packer RJ, Goldwein J, Nicholson HS, et al: Treatment of children with medulloblastomas with reduced-dose craniospinal radiation therapy and adjuvant chemotherapy: A Children's Cancer Group study. J Clin Oncol 17:2127-2136, 1999
13. Packer RJ, Gajjar A, Vezina G, et al: Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed averagerisk medulloblastoma. J Clin Oncol 24:4202-4208, 2006
14. Miralbell R, Fitzgerald TJ, Laurie F, et al: Radiotherapy in pediatric medulloblastoma: Quality assessment of Pediatric Oncology Group Trial 9031. Int J Radiat Oncol Biol Phys 64:1325-1330, 2006
15. Strother D, Ashley D, Kellie SJ, et al: Feasibility of four consecutive high-dose chemotherapy cycles with stem-cell rescue for patients with newly diagnosed medulloblastoma or supratentorial primitive neuroectodermal tumor after craniospinal radiotherapy: Results of a collaborative study. J Clin Oncol 19:2696-2704, 2001
16. Chan AW, Tarbell NJ, Black PM, et al: Adult medulloblastoma: Prognostic factors and patterns of relapse. Neurosurgery 47:623-631, 2000
17. Miralbell R, Bleher A, Huguenin P, et al: Pediatric medulloblastoma: Radiation treatment technique and patterns of failure. Int J Radiat Oncol Biol Phys 37:523-529, 1997
18. Thomas PR, Deutsch M, Kepner JL, et al: Lowstage medulloblastoma: Final analysis of trial comparing standard-dose with reduced-dose neuraxis irradiation. J Clin Oncol 18:3004-3011, 2000
19. del Charco JO, Bolek TW, McCollough WM, et al: Medulloblastoma: Time-dose relationship based on a 30-year review. Int J Radiat Oncol Biol Phys 42:147-154, 1998
20. Taylor RE, Bailey CC, Robinson K, et al: Results of a randomized study of preradiation chemotherapy versus radiotherapy alone for nonmetastatic medulloblastoma: The International Society of Paediatric Oncology/United Kingdom Children's Cancer Study Group PNET-3 Study. J Clin Oncol 21:1581-1591, 2003
21. Papadakis V, Dunkel IJ, Cramer LD, et al: High-dose carmustine, thiotepa and etoposide followed by autologous bone marrow rescue for the treatment of high risk central nervous system tumors. Bone Marrow Transplant 26:153-160, 2000